Cargando…

Nanovaccines against Viral Infectious Diseases

Infectious diseases have always been regarded as one of the greatest global threats for the last century. The current ongoing COVID-19 pandemic caused by SARS-CoV-2 is living proof that the world is still threatened by emerging infectious diseases. Morbidity and mortality rates of diseases caused by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heng, Wen Tzuen, Yew, Jia Sheng, Poh, Chit Laa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784285/ https://www.ncbi.nlm.nih.gov/pubmed/36559049 http://dx.doi.org/10.3390/pharmaceutics14122554

Ejemplares similares

Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins
por: Jazayeri, Seyed Davoud, et al.
Publicado: (2019)

Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease
por: Anasir, Mohd Ishtiaq, et al.
Publicado: (2019)

The development of DNA vaccines against SARS-CoV-2
por: Khalid, Kanwal, et al.
Publicado: (2023)

Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
por: Jazayeri, Seyed Davoud, et al.
Publicado: (2021)

Recent advances in delivery of veterinary DNA vaccines against avian pathogens
por: Jazayeri, Seyed Davoud, et al.
Publicado: (2019)

The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria
por: Khalid, Kanwal, et al.
Publicado: (2023)

Structural Vaccinology for Viral Vaccine Design
por: Anasir, Mohd Ishtiaq, et al.
Publicado: (2019)

Development of Novel Vaccines against Enterovirus-71
por: Yee, Pinn Tsin Isabel, et al.
Publicado: (2015)

Insights into innate and adaptive immune responses in vaccine development against EV-A71
por: Lim, Hui Xuan, et al.
Publicado: (2019)

Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases
por: Sengupta, Anirban, et al.
Publicado: (2022)

Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus
por: Anasir, Mohd Ishtiaq, et al.
Publicado: (2020)

Molecular Mechanisms of Antiviral Agents against Dengue Virus
por: Lee, Michelle Felicia, et al.
Publicado: (2023)

Development of MicroRNAs as Potential Therapeutics against Cancer
por: Abd-Aziz, Noraini, et al.
Publicado: (2020)

Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease
por: Lalani, Salima, et al.
Publicado: (2021)

The Conserved Molecular Determinants of Virulence in Dengue Virus
por: Ahmad, Zuleeza, et al.
Publicado: (2019)

Flavonoids as Antiviral Agents for Enterovirus A71 (EV-A71)
por: Lalani, Salima, et al.
Publicado: (2020)

Changes in the EV-A71 Genome through Recombination and Spontaneous Mutations: Impact on Virulence
por: Mandary, Madiiha Bibi, et al.
Publicado: (2018)

Functional Insights into Silymarin as an Antiviral Agent against Enterovirus A71 (EV-A71)
por: Lalani, Salima, et al.
Publicado: (2021)

Nanovaccines against Animal Pathogens: The Latest Findings
por: Celis-Giraldo, Carmen Teresa, et al.
Publicado: (2021)

Antiviral activity of silymarin in comparison with baicalein against EV-A71
por: Lalani, Salima S., et al.
Publicado: (2020)

Peptides as Therapeutic Agents for Dengue Virus
por: Chew, Miaw-Fang, et al.
Publicado: (2017)

Development of Peptide-Based Vaccines for Cancer
por: Abd-Aziz, Noraini, et al.
Publicado: (2022)

T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development
por: Yee, Pinn Tsin Isabel, et al.
Publicado: (2018)

Construction of an infectious cDNA clone of Enterovirus 71: Insights into the factors ensuring experimental success
por: Lazouskaya, Natallia V., et al.
Publicado: (2014)

Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
por: Al-Fattah Yahaya, Abdul Aziz, et al.
Publicado: (2023)

Artificially cloaked viral nanovaccine for cancer immunotherapy
por: Fusciello, Manlio, et al.
Publicado: (2019)

Impact of RNA Virus Evolution on Quasispecies Formation and Virulence
por: Mandary, Madiiha Bibi, et al.
Publicado: (2019)

Antivirals blocking entry of enteroviruses and therapeutic potential
por: Anasir, Mohd Ishtiaq, et al.
Publicado: (2021)

Development of multi-epitope peptide-based vaccines against SARS-CoV-2
por: Lim, Hui Xuan, et al.
Publicado: (2021)

Correction: Lalani, S. and Poh, C.L. Flavonoids as Antiviral Agents for Enterovirus A71 (EV-A71). Viruses 2020, 12, 184
por: Lalani, Salima, et al.
Publicado: (2020)

Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers
por: Lim, Hui Xuan, et al.
Publicado: (2020)

Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery
por: Essa, Raahilah Zahir, et al.
Publicado: (2022)

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection
por: Masomian, Malihe, et al.
Publicado: (2020)

Self-adjuvanting cancer nanovaccines
por: Liao, Zhiyun, et al.
Publicado: (2022)

Addressing Nanovaccine Strategies for Tilapia
por: Thompson, Kim D., et al.
Publicado: (2023)

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review
por: Asadi, Khatereh, et al.
Publicado: (2021)

CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021)

Role of NKT Cells during Viral Infection and the Development of NKT Cell-Based Nanovaccines
por: Khan, Masood Alam, et al.
Publicado: (2021)

Mucosal delivery of nanovaccine strategy against COVID-19 and its variants
por: Lee, Junwoo, et al.
Publicado: (2023)

Role of microRNAs in antiviral responses to dengue infection
por: Wong, Rui Rui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_doe4uhv3atg5tfgdk1pgkssuem